IL6 and COVID-19: Moreover, preliminary clinical data showed the effective treatment of severe and critical COVID-19 patients by a recombinant humanized anti-human IL-6 receptor monoclonal antibody tocilizumab, suggesting the potential therapeutic strategy via interfering of IL-6 35.